Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL360933 | 0.87 | ALDH1A1 (0.50) | ALDH1A1USP2SMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL28159237 | 0.84 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL1921973 | 0.84 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| Morpholine SCHEMBL8176978 | 0.80 | MEN1 (0.55) | ALDH1A1MEN1KMT2A | |
| Dioxane SCHEMBL8962544 | 0.76 | — | — | |
| Fluoride SCHEMBL15135042 | 0.76 | ALDH1A1 (0.80) | ALDH1A1 | |
| Fluoride SCHEMBL2684369 | 0.76 | ALDH1A1 (0.80) | ALDH1A1 | |
| SCHEMBL6223 | 0.76 | — | — | |
| SCHEMBL503396 | 0.76 | — | — | |
| SCHEMBL8679785 | 0.76 | ALDH1A1 (1.00) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385918-A | Novel midazolam crystal form and preparation method thereof | 成都硕德药业有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-2648726-B1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | claimed |
| CN-103596566-B | Polycyclic LPA1Antagonists and uses thereof | 阿米拉制药公司 | 2017-08-25 | — | — | CN | claimed |
| US-9556133-B2 | Polycyclic LPA1 antagonist and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | claimed |
| US-20130253023-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-26 | — | — | US | claimed |
| WO-2004083180-A1 | NOVEL CRYSTALLINE FORMS OF LEVETIRACETAM | HETERO DRUGS LIMITED (IN) | 2004-09-30 | — | — | WO | claimed |
| CN-117916233-A | Amorphous, crystalline, pharmaceutical compositions, methods of preparation and uses of thiohydantoin compounds or pharmaceutically acceptable salts thereof | 苏州开拓药业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024017266-A1 | POLYMORPHIC FORM OF GLP-1R AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | 德睿智药(苏州)新药研发有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-117088902-A | Preparation method of boron carrying agent by one-pot method | 苏州博锐创合医药有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-115385918-A | Novel midazolam crystal form and preparation method thereof | 成都硕德药业有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-10562927-B2 | Bismuth perfluoroalkylphosphinates as lewis acid catalysts | MERCK PATENT GMBH (DE) | 2020-02-18 | — | — | US | disclosed |
| US-10328423-B2 | Perfluoroalkyl group-containing bismuth compounds as lewis acid catalysts | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20180290964-A1 | CRYSTALLINE SOLID FORMS OF THE ACETATE SALT OF (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)-7A-METHYL-1-METHYLENEOCTAHYDRO-1H-INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXANOL | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-10-11 | — | — | US | disclosed |
| WO-2010027448-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-7271296-B2 | Method for the production of phytofluene | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-18 | — | — | US | disclosed |
| US-20070004925-A1 | Method for the production of phytofluene | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-04 | — | — | US | disclosed |
| US-20050143445-A1 | Novel crystalline forms of levetiracetam | HETERO DRUGS LIMITED (IN) | 2005-06-30 | — | — | US | disclosed |
| WO-2004083180-A1 | NOVEL CRYSTALLINE FORMS OF LEVETIRACETAM | HETERO DRUGS LIMITED (IN) | 2004-09-30 | — | — | WO | disclosed |
| EP-1051402-A1 | METHOD FOR PRODUCING S-ALKYL(ARYL)-SUBSTITUTED IMIDAZOL DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037620-A1 | METHOD FOR PRODUCING S-ALKYL(ARYL)-SUBSTITUTED IMIDAZOL DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562927-B2 | Bismuth perfluoroalkylphosphinates as lewis acid catalysts | FXR2, PRXL2A, AFF2 | ALDH1A1 827/4885TTR 1596/4885USP2 223/4885 |
| US-20130253023-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | LPAR1, LPAR2, LPAR4 | ALDH1A1 1515/4885TTR 3675/4885USP2 3784/4885 |
| US-20180290964-A1 | CRYSTALLINE SOLID FORMS OF THE ACETATE SALT OF (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)-7A-METHYL-1-METHYLENEOCTAHYDRO-1H-INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXANOL | HSD3B1, CYP4A11, CYP2S1 | ALDH1A1 263/4885TTR 761/4885USP2 3932/4885 |
| US-20050143445-A1 | Novel crystalline forms of levetiracetam | EPM2A, MAPT, ATG4A | ALDH1A1 2664/4885TTR 6/4885USP2 1806/4885 |
| US-10328423-B2 | Perfluoroalkyl group-containing bismuth compounds as lewis acid catalysts | AFF4, PFAS, FAH | ALDH1A1 2148/4885TTR 1401/4885USP2 192/4885 |
| US-20070004925-A1 | Method for the production of phytofluene | AKR1C4, F12, F5 | ALDH1A1 458/4885TTR 2758/4885USP2 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.